Two doses of the widely used HPV vaccine Gardasil9 produced an immune response identical to the standard three-dose regimen in women with well-controlled HIV, according to a study by Dr Deborah Konopn...

Norge går for den billigste HPV-vaksinen. Det kan bli dyrt i lengden.

A Scottish study found that the HPV vaccine is effective in preventing cervical cancer, with zero cases among women vaccinated at ages 12-13.

Information about HPV vaccination and certain-HPV related cancers.

Two doses of the widely used HPV vaccine Gardasil9 produced an immune response identical to the standard three-dose regimen in women with well-controlled HIV, according to a study by Dr Deborah Konopnicki and colleagues published in the journal Clinical Infectious Diseases.

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV) virus-like particle (VLP) vaccines in young women are now lar…

Many Americans remain unaware of the cancer risk for both men and women posed by human papillomavirus (HPV), a new Ohio State University poll has found. Most pe

Norge fortsetter med Cervarix-vaksinen i kampen mot HPV-virus. Grete Godtlibsen Dale betaler for Gardasil9-vaksiner til barna sine av egen lomme.

WHO recommends 2 doses of HPV vaccine for adults without HIV but 3 doses in persons with HIV. There are no immunogenicity data on the 2 doses schedule in women with HIV (WWH).MethodsProspective study comparing 2 (month (M) 0,6) versus 3 (M 0,2,6) doses of 9-valent (9v) vaccine (Gardasil9®MSD) in WWH (15-40 years), on antiretrovirals with HIVRNA<400cp/ml; enrollment 2018-2021. After an open-label phase assessing safety (n=45 receiving 3 doses), participants were randomized between 2 or 3 doses. Primary outcome was non-inferiority of 2 doses compared to 3 doses for seroconversion against all vaccine genotypes. Due to COVID-19 pandemic, 100 WWH, instead of initially planned 120, were randomized. The trial was further amended to give 2 doses to all participants enrolled thereafter (n=22). Results were analyzed in modified intention-to-treat (mITT) on the randomized cohort (n=100) and Per Protocol (PP) on the whole cohort (n=167).ResultsMedian age was 35 years, median CD4 count 649/µL, 16 missed M7 visit. In mITT, seroconversion was 97.7% for 2 doses and 97.9% for 3 doses, meeting the predefined non-inferiority criteria. At M7, antibodies titers against all vaccine genotypes were high in both groups (increase by 1.2-2.4 log10). There was no serious adverse event; participants with 3 doses experienced local reaction more frequently (82% versus 60% for 2 doses, p=0.027) with significantly more symptoms and longer duration.ConclusionsIn women with well-controlled HIV, 2 doses of HPV 9v-vaccine is non-inferior to 3 doses in terms of seroconversion and is associated with less reactogenicity.